Systemic Treatment of Thyroid Cancer: ASCO Guideline.
review · Level I
Where this comes from
- Record sourced from PubMed, PMID 41921121.
- Also identified by DOI 10.1200/JCO-26-00235.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. A total of 66 publications were identified to inform the evidence base for this guideline. Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.Additional information is available at www.asco.org/head-neck-cancer-guidelines.